Paul Rennert

Paul is a noted research scientist and biotechnology executive with extensive strategic and leadership experience. His industry expertise spans bench to IND to clinical trials for biologics, small molecules and cellular therapeutics.

Paul’s recent accomplishments include the launch of successful new biotech companies. In 2012 he engaged with MPM Capital to launch CoStim Pharmaceuticals, one of the first private immuno-oncology companies (bought by Novartis), In 2013 he partnered with X-Chem Inc to create X-Rx Discovery, a privately held drug discovery company focused on oncology, inflammation, and fibrosis that successfully out-licensed programs in oncology and fibrosis.

In 2016 Paul co-founded Aleta Biotherapeutics, a novel CAR T cell company that has since moved rapidly from bench to clinical development. Paul recently secured non-dilutive funding from Cancer Research UK to advance Aleta’s lead program through Phase 1 and 2a clinical trials, with trials set to begin in 2023 for patients at risk of relapse from CAR T cell therapy.

Paul’s ability to work so broadly across the industry grew from his outstanding early career at Repligen and Biogen and is highlighted by multiple successful drug-development campaigns, over 60 patents filed and granted, and approximately 100 peer-reviewed publications including publications in Nature Reviews Drug Discovery, Annual Reviews, Immunity, Journal of Experimental Medicine, Journal of Clinical Investigation, and PNAS USA. In 2015 he co-authored and edited the book “Novel Therapeutic Approaches to the Treatment of Cancer”, for Springer Nature.